Zhongke Yian Receives NMPA Approval for Innovative Sirolimus-Eluting Coronary Stent
ZhongKe Yian Medical Technology (Beijing) Co., Ltd. has secured approval from China’s National Medical Products...
NMPA Approves World’s First Plant-Based Human Albumin for Liver Cirrhosis Treatment
China’s National Medical Products Administration (NMPA) has approved the world’s first plant-based human albumin, a...
KANTE Biotech’s Yilijia Wins NMPA Category III License for Pancreatic Cancer Early Detection
KANTE (Shenzhen) Biotechnology Co., Ltd (“Kante-bio”) announced that it has received a Category III medical...
WuXi Biologics Passes FDA Pre-Approval Inspection with Zero Critical Findings
WuXi Biologics (HKG: 2269) announced on July 21, 2025, that five of its manufacturing facilities...
Jumpcan Pharmaceutical’s Jike Shu Approved by NMPA for Influenza A and B Treatment
Shanghai-based Jumpcan Pharmaceutical (SHA: 600566) announced that its independently developed Class 1 innovative drug, Jike...
CDE Seeks Feedback on 96th Batch of Chemical Generic Drug Reference Standards
China’s Center for Drug Evaluation (CDE) is currently seeking public feedback on the 96th batch...
Novo Nordisk’s Ozempic Approved for Kidney Protection in China, Pioneering Glycemic and Renal Control
The National Medical Products Administration has granted approval to Novo Nordisk’s (NYSE: NVO) once-weekly semaglutide...
Shanghai Wankexin Biotech to Acquire Stake in Chengdu Kanghua Biological for RMB 1.851 Billion
Shanghai Wankexin Biotechnology Partnership Enterprise (Limited Partnership) (“Wankexin Biotech”), a subsidiary of the Shanghai Biomedicine...
Hebei Implements Separate Payment for 57 Negotiated Drugs Starting August 1, 2025
The Hebei provincial healthcare security administration has issued the “Notice on Improving the Separate Payment...
Bayer and JD Health Collaborate on Dulcolax-Lactulose to Expand China’s Digestive-Health Market
Bayer (ETR: BAYN) and JD Health (HKG: 6618) have launched Dulcolax-branded lactulose in a pioneering...
Sarepta Therapeutics Announces 500 Employee Layoffs After FDA Elevidys Trial Suspension
US-based Sarepta Therapeutics, a subsidiary of Sanofi (NASDAQ: SNY), announced the layoff of approximately 500...
VivaVision Biotech Closes D2+ Funding Round, Advancing Ophthalmic Therapies
VivaVision Biotech recently announced the successful closing of its D2+ funding round, raising 140 million...
Youcare Pharma Subsidiary Gains NMPA Clearance for Phase I Study of siRNA Hypertension Drug YKYY029
China-based Youcare Pharma (SHA: 688658) announced that its subsidiary Youcare InnoTech and partner Hangzhou Tianlong...
GSK’s Blenrep Fails to Win FDA Advisory Committee Support for Relapsed Multiple Myeloma
UK-based GlaxoSmithKline (GSK; NYSE: GSK) announced that the US Food and Drug Administration (FDA) Oncologic...
Robo Medical Secures Tens of Millions in Funding for EndoFaster and EndoDreams Development
China-based Robo Medical Technology Co. has closed a strategic funding round amounting to “tens of...
CanSino Bio Receives NMPA Approval for Phase I/II Trial of Recombinant Polio Vaccine
China-based CanSino Biologics Inc., (HKG: 6185) announced that it and its subsidiary CanSino (Shanghai) Biotechnology...
Yifan Pharma’s Generic Glycerol Phenylbutyrate Accepted for NMPA Review
China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced that the National Medical Products Administration (NMPA)...
Hengrui Pharmaceuticals’ SHR-8068 Gains NMPA Approval for NSCLC and Colorectal Cancer Trials
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that the National Medical...
Fosun Pharma’s Zhejiang Xinghao Unit Initiates Phase Ib Study for COPD DPP-1 Inhibitor XH-S004
Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its Zhejiang Xinghao...
Legend Biotech’s Carvykti Achieves USD 439 Million in Q2 2025 Sales
China-based Legend Biotech Corporation (NASDAQ: LEGN) reported that sales of Carvykti reached USD 439 million...